Group 1 - The core viewpoint of the news is that Beijing Baipusi Biotechnology Co., Ltd. has seen a stock price increase of 5.03%, reaching 61.21 yuan per share, with a total market capitalization of 10.274 billion yuan as of October 21 [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - From the perspective of fund holdings, Yinhua Fund has a significant position in Baipusi, with the Yinhua Healthcare Mixed A Fund (018364) holding 40,500 shares, accounting for 5.42% of the fund's net value, making it the third-largest holding [2] - The Yinhua Healthcare Mixed A Fund was established on September 6, 2023, with a current scale of 35.6523 million yuan, and has achieved a year-to-date return of 8.54% [2] Group 3 - The fund managers of Yinhua Healthcare Mixed A Fund are Zhang Ping and Wang Lu, with Zhang having a tenure of 6 years and 352 days and a total asset scale of 20.578 billion yuan, while Wang has a tenure of 2 years and 292 days with an asset scale of 2.301 billion yuan [3]
百普赛斯股价涨5.03%，银华基金旗下1只基金重仓，持有4.05万股浮盈赚取11.87万元